Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmruTWM2OD1yLkCwOlY6KM7:TR?= NXXTUnhrW0GQR1XS
MV-4-11 NIi0UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEG1PFYh|ryP NXHNNVE2W0GQR1XS
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEG2PVkh|ryP M2q3eXNCVkeHUh?=
ML-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XWZmlEPTB;MD6wNVk5OyEQvF2= NULtXI56W0GQR1XS
BV-173 M{L3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEKzNVQh|ryP M3TvWnNCVkeHUh?=
RS4-11 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEK1PFch|ryP M1XRXHNCVkeHUh?=
HL-60 NH2x[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEK5NFgh|ryP M2HxTnNCVkeHUh?=
KY821 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX5TWM2OD1yLkCyPVc2KM7:TR?= M33ucXNCVkeHUh?=
ECC10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HJOmlEPTB;MD6wN|c6OiEQvF2= Mlq0V2FPT0WU
NCI-H720 NYXTdWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMESwNVEh|ryP MWPTRW5ITVJ?
QIMR-WIL MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4SldKSzVyPUCuNFQzQDdizszN M{DsdnNCVkeHUh?=
KG-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnUV4ZKSzVyPUCuNFQ1QDZizszN MV3TRW5ITVJ?
TGW NGXh[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMES2N|Mh|ryP Mn[1V2FPT0WU
ATN-1 M4DrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHqdYI1UUN3ME2wMlA1PzN|IN88US=> NFH2VlVUSU6JRWK=
RH-18 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ETWM2OD1yLkC2NFQ5KM7:TR?= MUfTRW5ITVJ?
EW-18 M{OzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXsSJU{UUN3ME2wMlA3QDRzIN88US=> MV3TRW5ITVJ?
NB17 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEexNlQh|ryP NGDS[pdUSU6JRWK=
SK-NEP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX0TWM2OD1yLkC3NlE{KM7:TR?= MVPTRW5ITVJ?
P12-ICHIKAWA NILPdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHSZWRKSzVyPUCuNFc4PzhizszN NWnWSpdJW0GQR1XS
KARPAS-45 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DPbWlEPTB;MD6wO|gyPSEQvF2= MXXTRW5ITVJ?
EW-3 M3PpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e5b2lEPTB;MD6wPFA2OyEQvF2= MVPTRW5ITVJ?
NB13 M17pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7wUmdKSzVyPUCuNFgzODNizszN MoCyV2FPT0WU
NCI-H209 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEi3NFQh|ryP MXXTRW5ITVJ?
NCI-H1092 NVTqXmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3UfIJKSzVyPUCuNVAzPzVizszN NFfNe5pUSU6JRWK=
NH-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMUC3OFQh|ryP NXGzNYNpW0GQR1XS
697 M2\Y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfsSJdKSzVyPUCuNVA5OzlizszN NYfF[Zd5W0GQR1XS
KE-37 M1T1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPTWM2OD1yLkGxN|ch|ryP NH;CbJRUSU6JRWK=
MOLT-4 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Wb2lEPTB;MD6xOVE3QSEQvF2= MWLTRW5ITVJ?
CHP-134 M1GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfZNmRKSzVyPUCuNVY{ODZizszN NVTme5lqW0GQR1XS
D-283MED NXewTJd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv5TWM2OD1yLkG3Olg3KM7:TR?= MWjTRW5ITVJ?
LU-135 NYqwXoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj0NoVKSzVyPUCuNVg2PTJizszN NHz1S2dUSU6JRWK=
LU-134-A M4rKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;jfnpKSzVyPUCuNVg3PzFizszN MoTyV2FPT0WU
EM-2 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUm5NVgh|ryP MUTTRW5ITVJ?
LU-139 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKW3RTUUN3ME2wMlIxPDl6IN88US=> NH72PGpUSU6JRWK=
ALL-PO NGXpTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7rU5JsUUN3ME2wMlIyQTh6IN88US=> MkHxV2FPT0WU
NB12 NEPMXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LqfWlEPTB;MD6yN|EyPSEQvF2= M13ZbnNCVkeHUh?=
KP-N-YN M2TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvV[IE6UUN3ME2wMlI{PTd|IN88US=> M4PvSHNCVkeHUh?=
BEN NHTjUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTJfYR7UUN3ME2wMlI{QTZ6IN88US=> MnvwV2FPT0WU
HCC1569 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMkWxNFYh|ryP NV3VTGozW0GQR1XS
HuO9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyT2lEPTB;MD6yOlcyPSEQvF2= M1XSWXNCVkeHUh?=
WM-115 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvxUGxKSzVyPUCuNlc4OzhizszN M2n0[HNCVkeHUh?=
CCRF-CEM NFHET3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnCOHhKSzVyPUCuN|M2OjlizszN MXrTRW5ITVJ?
IST-SL1 NGDCdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXxSnpKSzVyPUCuN|U{PDNizszN NFWye4hUSU6JRWK=
BE-13 NV;sUpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwM{[0OVkh|ryP NVHOXpVqW0GQR1XS
COR-L88 NXXvcWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPjcoFYUUN3ME2wMlM3PTRizszN MY\TRW5ITVJ?
DOHH-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwNEGwNlMh|ryP NUGyZ2NRW0GQR1XS
A704 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXwTWM2OD1yLkSyOlch|ryP Mny4V2FPT0WU
KNS-81-FD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNESwNVch|ryP NIrBeIhUSU6JRWK=
RPMI-8226 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1yLkS1OlUzKM7:TR?= NHLyOHVUSU6JRWK=
TGBC24TKB NWfMSXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy2e3RKSzVyPUCuOFU4PzhizszN M{HLTnNCVkeHUh?=
NCI-H1304 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPLSlVKSzVyPUCuOFYyPTdizszN Mo\EV2FPT0WU
MOLT-13 NYLhdZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1e2JKSzVyPUCuOFY3OTNizszN NV:3bHVqW0GQR1XS
EW-22 NYX4XJBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNE[2O|Eh|ryP NVnKUWtRW0GQR1XS
MS-1 NYDabGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;QTWM2OD1yLkS2PVM{KM7:TR?= MmXsV2FPT0WU
RMG-I MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW3TWM2OD1yLkS5OFY1KM7:TR?= NEf5S5ZUSU6JRWK=
NTERA-S-cl-D1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HBXmlEPTB;MD61NFAyQSEQvF2= MVPTRW5ITVJ?
NCI-H1048 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki2TWM2OD1yLkWwPVU{KM7:TR?= MV7TRW5ITVJ?
SW1417 M4LoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzOTWM2OD1yLkW1OFM5KM7:TR?= MYLTRW5ITVJ?
DB NGjWW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHCenp[UUN3ME2wMlU4ODhizszN NH7RZYpUSU6JRWK=
MEG-01 NHrobG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyTWM2OD1yLkW4N|Ih|ryP NHTJ[G5USU6JRWK=
EW-13 M1PnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7zTWM2OD1yLkW4N|QyKM7:TR?= Ml3IV2FPT0WU
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX23W|Y3UUN3ME2wMlU6OjB5IN88US=> MWPTRW5ITVJ?
J-RT3-T3-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwNkC4NFgh|ryP MWnTRW5ITVJ?
MOLT-16 NYS3XYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW2W2NKSzVyPUCuOlUzPjRizszN MUDTRW5ITVJ?
DU-4475 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX1fotwUUN3ME2wMlY2PDJ5IN88US=> MnfqV2FPT0WU
HAL-01 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIflS3JKSzVyPUCuO|I2PDlizszN NVXUfIZwW0GQR1XS
RD NYn2VFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwN{W4PVkh|ryP NYXYNJdEW0GQR1XS
OAW-28 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1focmlEPTB;MD63PFM4KM7:TR?= NWXMT3N6W0GQR1XS
HCC38 M{HsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfJTWM2OD1yLkiwNVkh|ryP NWeyNmFpW0GQR1XS
NMC-G1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwOEGxNlEh|ryP M{XDcHNCVkeHUh?=
EW-16 NGjXe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwOEGzNlgh|ryP NIqyRVlUSU6JRWK=
DU-145 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwOEm5NlMh|ryP MULTRW5ITVJ?
HPAF-II M4LVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3TFlmUUN3ME2wMlkzPjJ6IN88US=> NXuyeHRuW0GQR1XS
A427 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DZc2lEPTB;MD65N|AzOiEQvF2= MmDSV2FPT0WU
PA-1 NGHjTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPuZYhKSzVyPUCuPVU3PDJizszN NUXNNWdDW0GQR1XS
OAW-42 NV7SS3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjmZmt2UUN3ME2wMlk3OTR4IN88US=> M37OS3NCVkeHUh?=
L-428 NGPQTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljsTWM2OD1zLkCxNlUh|ryP NWf0XHRqW0GQR1XS
COLO-824 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m5SmlEPTB;MT6wNVcxQCEQvF2= Mon5V2FPT0WU
P30-OHK NHHP[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rX[WlEPTB;MT6wOFY5QCEQvF2= MojiV2FPT0WU
NCI-H2170 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[xTWM2OD1zLkC2NlMh|ryP M3vWdXNCVkeHUh?=
HCC2998 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtPGlEPTB;MT6wO|E{PSEQvF2= MoG3V2FPT0WU
NB14 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMUO3OFgh|ryP M3nmS3NCVkeHUh?=
TGBC1TKB NYjZcWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTxTWM2OD1zLkG0NVUzKM7:TR?= NH\nU3VUSU6JRWK=
KP-N-YS NWrEcmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XxXWlEPTB;MT6xOlI{PiEQvF2= NUfibpEyW0GQR1XS
CAL-120 M{HyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMU[0Nlkh|ryP MofSV2FPT0WU
SBC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMUmwOVMh|ryP MmLyV2FPT0WU
C32 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwMUmwPFgh|ryP M{nDTXNCVkeHUh?=
HCC2157 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nSOGlEPTB;MT6xPVQ6PCEQvF2= NVrSWJRXW0GQR1XS
COLO-792 NH7v[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfkTWM2OD1zLkKwNFcyKM7:TR?= NHnyXJRUSU6JRWK=
ES7 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMke5OVEh|ryP M4HQTXNCVkeHUh?=
HEL Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHjTWM2OD1zLkOxNFI6KM7:TR?= NYXDbIp7W0GQR1XS
ES4 NUnkcHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\oTWM2OD1zLkO0PVk5KM7:TR?= MlLDV2FPT0WU
NCI-SNU-1 M33SbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwM{[1OVUh|ryP NITsfWtUSU6JRWK=
MDA-MB-415 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PRcGlEPTB;MT6zPFg2KM7:TR?= M{HZVnNCVkeHUh?=
NCI-H2342 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwNECyOlkh|ryP NWLRdI4{W0GQR1XS
NB69 NHXERmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH25UlNKSzVyPUGuOFYzPzFizszN Mo\DV2FPT0WU
D-247MG NWDs[3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;DT2lEPTB;MT61NVEzOiEQvF2= Mlv2V2FPT0WU
SCC-4 NIrpNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwNUm4PFch|ryP NHrjS|hUSU6JRWK=
HuH-7 M2D3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PxW2lEPTB;MT62O|I6OyEQvF2= MoLrV2FPT0WU
A388 M3HjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2UJBSUUN3ME2xMlY5PzJ2IN88US=> NI\ZPINUSU6JRWK=
Calu-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFZodKSzVyPUGuO|A3QTdizszN NUS4PZFiW0GQR1XS
NCI-H1648 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwN{G0NVgh|ryP MYnTRW5ITVJ?
NCI-H2052 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTNPW5XUUN3ME2xMlczOjBzIN88US=> NHHTbmlUSU6JRWK=
Ramos-2G6-4C10 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwN{O2OVYh|ryP NG\RRoJUSU6JRWK=
DEL NGfwfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXXeFZKSzVyPUGuO|Q3QTJizszN M1WzUnNCVkeHUh?=
SNU-423 NF7jfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD1zLke4NVU4KM7:TR?= M4\xWnNCVkeHUh?=
COR-L23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDyTWM2OD1zLke5PFc1KM7:TR?= MlPGV2FPT0WU
OMC-1 NVTGbW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLPTWM2OD1zLki2NFE3KM7:TR?= M2[2e3NCVkeHUh?=
EW-11 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwOUW2OVch|ryP NYC5XFV5W0GQR1XS
HSC-3 NY\zbZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\LbmtKSzVyPUGuPVY{PjVizszN Mnv1V2FPT0WU
MLMA MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwOU[2O|ch|ryP MXHTRW5ITVJ?
RCM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fIUmlEPTB;Mj6wNFM6QSEQvF2= MVzTRW5ITVJ?
MFE-280 NIfYZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlTWM2OD1{LkCyPFQ5KM7:TR?= NW\ofWJNW0GQR1XS
ES8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkVHhKSzVyPUKuNlU1PzFizszN NWm1e2d6W0GQR1XS
TE-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHkTWM2OD1{LkK5OFc{KM7:TR?= MXTTRW5ITVJ?
HuO-3N1 NUS4XFd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzqTJhKSzVyPUKuOFg4QCEQvF2= NFrCV4tUSU6JRWK=
MHH-NB-11 M171Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJwNUGxOVgh|ryP NVvXNnE{W0GQR1XS
TGBC11TKB MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7MbGRKSzVyPUKuOVc3QDFizszN M2DEeXNCVkeHUh?=
HOP-92 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PTdmlEPTB;Mj61PFc1OyEQvF2= MoToV2FPT0WU
IGR-1 NGXXUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\SRYZKSzVyPUKuOlIxOzVizszN NWHzfYZxW0GQR1XS
GOTO NHi4OZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TNR2lEPTB;Mj62OVM4PyEQvF2= MWnTRW5ITVJ?
NCI-H1650 M4XYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLvVJBmUUN3ME2yMlczOjF3IN88US=> NWPDPHpFW0GQR1XS
NCI-H1581 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGweWhEUUN3ME2yMlc6PjhzIN88US=> NEPrboJUSU6JRWK=
NCI-H2405 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLPTWM2OD1{LkiyO|gzKM7:TR?= M4D5VHNCVkeHUh?=
U-118-MG MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pp[WlEPTB;Mj65OlQ6OSEQvF2= NVvWOHFJW0GQR1XS
DoTc2-4510 NWnkcWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwMEG0NVch|ryP NGLGd2RUSU6JRWK=
NCI-H596 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywWmlEPTB;Mz6wOFk6PyEQvF2= M3XX[XNCVkeHUh?=
MPP-89 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV33XWZDUUN3ME2zMlA2PjZ4IN88US=> MkPVV2FPT0WU
GCIY Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX3OlFKSzVyPUOuNlA1QTFizszN NWnIR282W0GQR1XS
SW626 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwMkS1OFMh|ryP Mnv1V2FPT0WU
OCI-AML2 NXG5eVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\DZWlEPTB;Mz6zNVI4OiEQvF2= NIHU[lBUSU6JRWK=
NBsusSR NFW1dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[z[HgzUUN3ME2zMlM1QTN6IN88US=> NVjUVJNbW0GQR1XS
AN3-CA MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwNESyN|gh|ryP NIHzNJZUSU6JRWK=
EFM-19 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD1|LkS4N|M6KM7:TR?= NHPhT4VUSU6JRWK=
RVH-421 NIf4[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsNGlEPTB;Mz61Olg4PyEQvF2= NFjYfpVUSU6JRWK=
5637 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO1OIlCUUN3ME2zMlYyOTB|IN88US=> NV3jb417W0GQR1XS
PANC-08-13 NHLSenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnvUIdKSzVyPUOuOlM1PzJizszN Mn\wV2FPT0WU
H9 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDMW2lKSzVyPUOuOlcyPDRizszN NHX4VItUSU6JRWK=
KARPAS-299 NV7UfHhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHxTWM2OD1|Lk[3N|YyKM7:TR?= M4nzZnNCVkeHUh?=
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVUWlEPTB;Mz63NFcxQSEQvF2= M1ziXXNCVkeHUh?=
NOS-1 NIC1PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TITGlEPTB;Mz63PVg{PCEQvF2= MWPTRW5ITVJ?
HH M3rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;wR5FKSzVyPUOuPFM5PjhizszN M4TWWHNCVkeHUh?=
769-P M4r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjNTWM2OD1|Lki5OVEh|ryP MXzTRW5ITVJ?
CHP-212 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C5N2lEPTB;Mz65NlU1QSEQvF2= NUXHPJJUW0GQR1XS
NCI-H82 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXIU2lKSzVyPUOuPVU6OzZizszN MoLMV2FPT0WU
Mo-T M{jpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjqVpJSUUN3ME20MlA1OzF{IN88US=> MWHTRW5ITVJ?
BB65-RCC NEPNUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXTe|RMUUN3ME20MlA1Ozl7IN88US=> NVX5foJtW0GQR1XS
SW1990 M2XzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;wRoVKSzVyPUSuNFU6ODhizszN MXfTRW5ITVJ?
LK-2 NW[2b4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TRNWlEPTB;ND6xNVI6OyEQvF2= MUHTRW5ITVJ?
ES5 M3fF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJV4dKSzVyPUSuNVM6QDVizszN M13YenNCVkeHUh?=
JVM-3 NHzmXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iwTGlEPTB;ND6xPFIzOiEQvF2= M2\2c3NCVkeHUh?=
RPMI-7951 NED1cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37PTWlEPTB;ND6yNlQyOyEQvF2= M3fObHNCVkeHUh?=
Calu-6 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RUG1KSzVyPUSuNlc5QDFizszN NUHoToxZW0GQR1XS
LC-2-ad NXvDT|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDVT2JKSzVyPUSuNlk2PjhizszN NH;ZUIJUSU6JRWK=
SW954 NFfXcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrRTWM2OD12LkK5OlYh|ryP MlTZV2FPT0WU
H-EMC-SS MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lq[mlEPTB;ND6zNVg{OSEQvF2= NWjZcIc1W0GQR1XS
ES3 M4nV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXKTWM2OD12LkO1OFQyKM7:TR?= MkDLV2FPT0WU
no-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHqTWM2OD12LkO1OVU1KM7:TR?= MoLjV2FPT0WU
LAN-6 NEXhUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqwNYNKSzVyPUSuOFUyQDlizszN NHzyZpZUSU6JRWK=
FTC-133 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\mVGlEPTB;ND61N|k2KM7:TR?= M3rYZXNCVkeHUh?=
8505C M2H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\aTWM2OD12LkW0NlMh|ryP NVLPSYo4W0GQR1XS
SW620 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYfIhKSzVyPUSuOVcxPTdizszN MYHTRW5ITVJ?
BCPAP NEHWc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrvbXJKSzVyPUSuOlM1QDFizszN NWS5TFRiW0GQR1XS
SK-LU-1 NY\NTpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PnemlEPTB;ND62OlA5QSEQvF2= M3;IWXNCVkeHUh?=
NCI-H1623 NEXzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrrTWM2OD12LkewNlI5KM7:TR?= NVu5[ZVpW0GQR1XS
C2BBe1 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:wfXhKSzVyPUSuO|QxODhizszN M4SwSXNCVkeHUh?=
GP5d NULs[YJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfyZZlKSzVyPUSuO|g{QDhizszN MVPTRW5ITVJ?
NB6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3SlFKSzVyPUSuPFYzODRizszN MV\TRW5ITVJ?
MDA-MB-157 M1LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXCTWM2OD12Lki4O|Yh|ryP NWrzfm9oW0GQR1XS
UMC-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwOEi5OlQh|ryP MUHTRW5ITVJ?
HCC1419 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPhTWM2OD12LkmwNFY{KM7:TR?= MYnTRW5ITVJ?
NCI-H2029 NX\HdWxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwOUSxPFUh|ryP MUDTRW5ITVJ?
LXF-289 NEjhNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPVcZk2UUN3ME21MlA{PzF7IN88US=> NX;h[od2W0GQR1XS
KINGS-1 NWDJN5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LIWGlEPTB;NT6wO|c1PCEQvF2= NFjTXIZUSU6JRWK=
HD-MY-Z MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUNYhKSzVyPUWuNlM6PjlizszN NFjQ[o1USU6JRWK=
ESS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfnZ2RlUUN3ME21MlI2PTl5IN88US=> NHvi[JFUSU6JRWK=
GI-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PPVWlEPTB;NT6yO|kzPiEQvF2= NXnrfGlzW0GQR1XS
RPMI-2650 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHCc5RKSzVyPUWuN|YyPiEQvF2= NUnOVoVxW0GQR1XS
IA-LM Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJTWM2OD13LkO5PFcyKM7:TR?= MkTZV2FPT0WU
KP-4 NHPDdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwNE[zN|Qh|ryP NV7IXoxUW0GQR1XS
G-402 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXri[FBuUUN3ME21MlUyQDZ3IN88US=> M{DvSHNCVkeHUh?=
OS-RC-2 NH30PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwNUK2NFQh|ryP M2jKVXNCVkeHUh?=
NCI-H1155 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3wVmF7UUN3ME21MlU1QTV3IN88US=> NW\OW2ZMW0GQR1XS
OE19 M3PYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2noR2lEPTB;NT62PFYzPCEQvF2= MYHTRW5ITVJ?
U-2-OS NGraRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrvfIVKSzVyPUWuPFkxOTNizszN M1TOWHNCVkeHUh?=
SCC-15 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzW4hIUUN3ME21Mlk{PjZ{IN88US=> MXLTRW5ITVJ?
NCI-H630 NU\uPGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[yTWM2OD13Lkm5OFA1KM7:TR?= MX3TRW5ITVJ?
PFSK-1 M{C4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZwMEWyOVkh|ryP M{m1WnNCVkeHUh?=
NCI-H1770 NGjRdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\HU3dKSzVyPU[uNlA5PzRizszN Ml65V2FPT0WU
SK-MEL-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwNEK5NVUh|ryP MXvTRW5ITVJ?
LB1047-RCC NUjPfGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjCZ|dKSzVyPU[uOFc3OjVizszN M1fMZXNCVkeHUh?=
NCI-H446 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZdmlEPTB;Nj62NlkzPSEQvF2= NVKxNpc1W0GQR1XS
SW780 M2TOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZwN{CxPFUh|ryP NF\6SIhUSU6JRWK=
NEC8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHBTWM2OD14Lke2OlMh|ryP NYXjUZAzW0GQR1XS
NOMO-1 M{OxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGT2FKSzVyPU[uO|gyOTFizszN MVPTRW5ITVJ?
COLO-668 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\a[ppKSzVyPU[uPFQ{QDdizszN MlXHV2FPT0WU
MC116 NGS3NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13uNGlEPTB;Nj65N|g6PyEQvF2= NWfZZ5Q6W0GQR1XS
HCC1937 NWjiXmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD14Lkm5NlUyKM7:TR?= Mn:wV2FPT0WU
NCI-N87 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxN2lEPTB;Nz6xPVI6OyEQvF2= NEn3cZBUSU6JRWK=
COLO-320-HSR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITI[2VKSzVyPUeuNlI4OzhizszN MnPBV2FPT0WU
HCC1806 M1KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37w[2lEPTB;Nz6yOlA1PCEQvF2= MlzBV2FPT0WU
OVCAR-3 M1jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTdwM{OwN|gh|ryP NES2N5NUSU6JRWK=
NUGC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XiWWlEPTB;Nz6zPVY6PCEQvF2= MU\TRW5ITVJ?
SW1783 NYPsVYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37EdGlEPTB;Nz60N|E4PSEQvF2= NV[2dGVGW0GQR1XS
GCT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdwNU[5NFYh|ryP NY[5eFdDW0GQR1XS
NCI-H2126 M3jiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTdwN{O2NlUh|ryP MYPTRW5ITVJ?
MEL-HO NYHsbnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTTWM2OD15Lke3NFU1KM7:TR?= MnPYV2FPT0WU
CAPAN-1 M4TNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPBVZRLUUN3ME23Mlc4OzV5IN88US=> NYL2dWFWW0GQR1XS
SW756 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTdwN{izN|Mh|ryP M4\FR3NCVkeHUh?=
SKG-IIIa NV7q[|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPkTWM2OD15LkixPFkzKM7:TR?= M1HYNnNCVkeHUh?=
HCE-T NIO3VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PT[mlEPTB;Nz64O|c5OyEQvF2= NYq3UHl6W0GQR1XS
Ca-Ski NVrsWGlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULXWYlzUUN3ME23Mlk6Ozh|IN88US=> MmfRV2FPT0WU
COLO-684 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLHR4pKSzVyPUiuNFE5OThizszN NFnkbZpUSU6JRWK=
KYSE-70 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS3TWM2OD16LkC3O|I6KM7:TR?= NVrid4V7W0GQR1XS
TI-73 M3WxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5TWM2OD16LkK1PFUyKM7:TR?= MnjqV2FPT0WU
BT-20 NEn0T49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRThwMk[wOVIh|ryP M3myU3NCVkeHUh?=
MHH-ES-1 NVvlNm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT5TWM2OD16LkWxPFM1KM7:TR?= M2jidXNCVkeHUh?=
TE-12 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiyTWM2OD16LkW5PVMyKM7:TR?= NYLhc2lYW0GQR1XS
YH-13 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRThwNkGwNFgh|ryP M3XFb3NCVkeHUh?=
SF126 NXr2OnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X0[WlEPTB;OD64N|g3PSEQvF2= NYHmbllxW0GQR1XS
J82 NXvJVoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5XWlEPTB;OD65NFA{QCEQvF2= NIHpSVRUSU6JRWK=
RCC10RGB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;WZWlEPTB;OD65PVU3OSEQvF2= NFjTcoNUSU6JRWK=
SK-UT-1 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTlwMES5OFUh|ryP M2ezZnNCVkeHUh?=
LB2241-RCC M4TZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\vfGlEPTB;OT6xPVE{PyEQvF2= NVf4TGE3W0GQR1XS
LB996-RCC NUTxbmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTlwMUm4PUDPxE1? NEPib4tUSU6JRWK=
EPLC-272H MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv2[2hLUUN3ME25MlM4PjV5IN88US=> NGL0VmZUSU6JRWK=
CTV-1 M{jiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDRd21KSzVyPUmuOVY2OzJizszN NXrkNYh{W0GQR1XS
HSC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILjWGlKSzVyPUmuOVc2PSEQvF2= MWDTRW5ITVJ?
SK-MEL-28 NVezRWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33rOWlEPTB;OT62NVg6OyEQvF2= MkG3V2FPT0WU
MMAC-SF MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3LN2dEUUN3ME25MlY5PzVizszN NGjnUXBUSU6JRWK=
CP50-MEL-B NYjCc29MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTlwN{W3PFIh|ryP NVHVT3pzW0GQR1XS
HT-1080 NYmweJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7BbIYxUUN3ME25Mlc4PzN7IN88US=> MY\TRW5ITVJ?
HEC-1 M{Cw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ixS2lEPTB;MUCuN|M2OiEQvF2= Mn;QV2FPT0WU
AGS MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFyLkO3OEDPxE1? MV7TRW5ITVJ?
GAMG M1HEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFyLkWxOlIh|ryP NYfae5dnW0GQR1XS
SW48 NEm5[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLxeFBKSzVyPUGwMlUyQDlizszN MXPTRW5ITVJ?
U031 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfIfpFKSzVyPUGwMlU6ODhizszN NInET5lUSU6JRWK=
OVCAR-5 M1i2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvVTWM2OD1zMD62OFI6KM7:TR?= NV;wUm1OW0GQR1XS
SF295 NFXxOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\OTWM2OD1zMD62O|A1KM7:TR?= MoPNV2FPT0WU
BHT-101 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLBTWM2OD1zMD63NVc4KM7:TR?= M1zuNXNCVkeHUh?=
VMRC-RCZ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTVGlEPTB;MUGuN|IxOSEQvF2= Mmn3V2FPT0WU
ACHN M1nMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFzLkSyNVEh|ryP MnrxV2FPT0WU
NCI-H526 NWjD[HRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnS[3FUUUN3ME2xNU42ODR|IN88US=> MYTTRW5ITVJ?
MN-60 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L3RmlEPTB;MUGuOVM6KM7:TR?= MnK0V2FPT0WU
NCI-H2291 NEPkclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\GOIpXUUN3ME2xNU42PDZ4IN88US=> NEHZZYFUSU6JRWK=
SCC-25 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5cYNKSzVyPUGxMlc2PTZizszN MUPTRW5ITVJ?
SK-MEL-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGxTFFKSzVyPUGxMlc3OzdizszN M3[3S3NCVkeHUh?=
SN12C NFLjOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPvTWM2OD1zMT65N|U2KM7:TR?= MonZV2FPT0WU
NCI-H69 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rrWmlEPTB;MUKuOFI{PCEQvF2= NWfReGkyW0GQR1XS
ME-180 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX24OHg{UUN3ME2xNk44ODV2IN88US=> MlHaV2FPT0WU
MC-IXC NYXOc4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;wNFQ{UUN3ME2xNk44PTF6IN88US=> NXrFSZFoW0GQR1XS
NCI-H2347 NXPuc412T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTJTWM2OD1zMj63OlE1KM7:TR?= M1O4VXNCVkeHUh?=
M059J MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLSOW11UUN3ME2xNk44PzJ5IN88US=> MVvTRW5ITVJ?
A2058 M{DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF{Lki2PFEh|ryP NVjiWGdQW0GQR1XS
VA-ES-BJ NXzkcJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHidIlKSzVyPUGyMlg4QDVizszN MnzuV2FPT0WU
Ca9-22 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3hO2VKSzVyPUGyMlk1PTFizszN M1PDR3NCVkeHUh?=
KNS-42 NFPOZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3hTWM2OD1zMj65PVg1KM7:TR?= NFm4VphUSU6JRWK=
LoVo M33nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTKTWM2OD1zMz6yN|E{KM7:TR?= NGCzb3lUSU6JRWK=
AM-38 M3jLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF|LkK1OlYh|ryP NHvJRWtUSU6JRWK=
NB5 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfwbpFnUUN3ME2xN{4{PzV{IN88US=> NYnFRWwyW0GQR1XS
L-363 NVnlc2V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G3S2lEPTB;MUOuOFA{OyEQvF2= M3HNd3NCVkeHUh?=
SK-MEL-30 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorsTWM2OD1zND6wOlQ2KM7:TR?= M3y4SHNCVkeHUh?=
NCI-H1563 M{\lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD1zND62NFM6KM7:TR?= MnW2V2FPT0WU
NCI-H2228 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF2Lk[wO|ch|ryP Mn3IV2FPT0WU
MFM-223 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHLTWM2OD1zNT6xPFE{KM7:TR?= MWTTRW5ITVJ?
LB831-BLC MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTNR5JKSzVyPUG1MlI4PjdizszN M1vMe3NCVkeHUh?=
SW872 NE\ZUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnBc|hvUUN3ME2xOU4{ODh4IN88US=> M{DjS3NCVkeHUh?=
NCI-H522 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LDOWlEPTB;MUWuN|MxPiEQvF2= NYL6e21iW0GQR1XS
EW-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FR2lEPTB;MUWuOVQ3OiEQvF2= MmT2V2FPT0WU
HN NY\aVVljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTwOnZKSzVyPUG1MlU6PDJizszN MlL3V2FPT0WU
SW837 M4\qbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD1zNT63PFQ4KM7:TR?= NUfYdJJJW0GQR1XS
SCC-9 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOz[4Q4UUN3ME2xOU45OTF2IN88US=> NWL5RpBzW0GQR1XS
MKN7 NH7GcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXyTWM2OD1zNT65O|MzKM7:TR?= MVLTRW5ITVJ?
KYSE-410 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETOWIpKSzVyPUG2MlU6OSEQvF2= NUHUeIJOW0GQR1XS
SK-N-DZ MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJWnNKSzVyPUG2MlYyOTZizszN MlXaV2FPT0WU
COR-L105 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF4Lk[1Nlgh|ryP M2DYVXNCVkeHUh?=
LB2518-MEL M1zLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjtT2lpUUN3ME2xOk45Ozh7IN88US=> NE[yXXNUSU6JRWK=
OVCAR-4 NIq5XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf1ZpNKSzVyPUG2Mlg5PjJizszN Ml3kV2FPT0WU
TK10 M4OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf5eGN6UUN3ME2xOk46PDd|IN88US=> Moj1V2FPT0WU
KNS-62 NGS0SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXiTWM2OD1zNj65O|c4KM7:TR?= NWi5dFJtW0GQR1XS
RPMI-8866 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LEZWlEPTB;MUeuNVc{OiEQvF2= NEfuR4lUSU6JRWK=
HuP-T4 M1v4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rVVGlEPTB;MUeuNlQ6PSEQvF2= NIDpRnNUSU6JRWK=
CGTH-W-1 NWfWd4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5LkWyNVkh|ryP NWrYTXVpW0GQR1XS
T-24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET4co1KSzVyPUG3MlU{PDdizszN MlTKV2FPT0WU
HT-3 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQRnk1UUN3ME2xO{42QTF2IN88US=> M3PCUnNCVkeHUh?=
KS-1 NXq2PYdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LUVWlEPTB;MUeuOlc{KM7:TR?= NG[weXNUSU6JRWK=
NCI-H1792 M3PFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF5Lke5PEDPxE1? MoHPV2FPT0WU
ABC-1 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[1OWN7UUN3ME2xO{45OTRzIN88US=> MWDTRW5ITVJ?
BPH-1 NXH3TGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfFXHZKSzVyPUG4MlE3QDVizszN MXrTRW5ITVJ?
A431 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF6LkSxNlch|ryP MmfNV2FPT0WU
T98G Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF6LkWxOVch|ryP MUHTRW5ITVJ?
BHY NYPvVnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF6Lki2PUDPxE1? MVjTRW5ITVJ?
Capan-2 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP1UFdKSzVyPUG4MlkxPzhizszN MmHKV2FPT0WU
MDA-MB-175-VII M3\UUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W2[2lEPTB;MUiuPVIxQSEQvF2= MXPTRW5ITVJ?
CAL-27 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVixcFViUUN3ME2xPU4xPDh5IN88US=> NHLod4VUSU6JRWK=
AsPC-1 MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fWS2lEPTB;MUmuPFY2PyEQvF2= MkTVV2FPT0WU
KU812 M4D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnNpdKSzVyPUG5Mlk2PzNizszN NW\LWVJkW0GQR1XS
NCI-H441 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3IdIpKSzVyPUKwMlAxOSEQvF2= NY\GflRuW0GQR1XS
Mewo NYHtb2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJyLkGyPFgh|ryP M2TBWnNCVkeHUh?=
SK-MEL-24 M{P3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PiTmlEPTB;MkCuNVQ4PyEQvF2= MVnTRW5ITVJ?
NCI-H727 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJyLkK3NFQh|ryP MWrTRW5ITVJ?
EKVX MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXsWHpYUUN3ME2yNE43ODZizszN MXvTRW5ITVJ?
RT-112 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLndmdOUUN3ME2yNE43OTJ{IN88US=> NEC1NHFUSU6JRWK=
CAMA-1 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;pdlNKSzVyPUKwMlk5ODNizszN M3rpeHNCVkeHUh?=
SW900 M1S5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnj[3ZKSzVyPUKxMlAyPDlizszN M3vhPHNCVkeHUh?=
NCI-H23 M{n2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lcWlEPTB;MkGuNVI4PyEQvF2= NUL2PXdDW0GQR1XS
SK-PN-DW M16zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnSTWM2OD1{MT6xOlQ6KM7:TR?= MlLxV2FPT0WU
BB30-HNC NYfsWZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvIPYlGUUN3ME2yNU4zPzR3IN88US=> NVvVW25KW0GQR1XS
VM-CUB-1 NYq5R25vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLxbWpKSzVyPUKxMlM2OzZizszN NF:3TmNUSU6JRWK=
IST-MEL1 NVyzRlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TlcWlEPTB;MkGuN|Y6OiEQvF2= M2jz[nNCVkeHUh?=
CTB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImwNWNKSzVyPUKxMlQ4PTVizszN M4HmbHNCVkeHUh?=
LCLC-103H M4PuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ{LkG1PFIh|ryP MmTLV2FPT0WU
PANC-03-27 NViydWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITpWmhKSzVyPUKyMlUyPjlizszN NIfkcpVUSU6JRWK=
HTC-C3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\rfIRnUUN3ME2yNk42PTV3IN88US=> NFr4cYRUSU6JRWK=
TE-8 NF6yO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73WJBKSzVyPUKzMlI2PjVizszN MYXTRW5ITVJ?
NCI-H292 NYLFdlNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLCZVg4UUN3ME2yOU4{PTN4IN88US=> MnHWV2FPT0WU
COLO-680N MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHns[2FKSzVyPUK1MlY{OjlizszN MlPHV2FPT0WU
KYSE-520 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD1{NT62OFQh|ryP M{P2PHNCVkeHUh?=
NB10 NYnWcplbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH2TWM2OD1{Nj6zNVE4KM7:TR?= MoP5V2FPT0WU
NCI-H661 NX:1Z3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrw[lJKSzVyPUK2MlQ4OTNizszN M1KzRnNCVkeHUh?=
GMS-10 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXTepNKUUN3ME2yOk45PjN6IN88US=> M13neHNCVkeHUh?=
NCI-H2122 NYrx[WF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjv[25KSzVyPUK2Mlk6QThizszN M17wR3NCVkeHUh?=
OVCAR-8 M2rDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ5LkC2N|gh|ryP NEjnUVNUSU6JRWK=
DJM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILIS45KSzVyPUK3MlE1PTRizszN NVrI[IpVW0GQR1XS
UACC-893 NWi2dm14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnYT5RJUUN3ME2yO{46QDd6IN88US=> NXTGbmFWW0GQR1XS
C8166 M3zUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO5ZXRSUUN3ME2yPE43QTN6IN88US=> NF7nTldUSU6JRWK=
NCI-H1693 NULyWldkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ6Lk[5O|Uh|ryP NXnhd4ZTW0GQR1XS
TYK-nu M4\ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJPGlEPTB;M{CuNFM1PSEQvF2= M2GweHNCVkeHUh?=
SW1710 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;zd4RKSzVyPUOwMlEzPiEQvF2= NGDqPZZUSU6JRWK=
A375 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXO[5hKSzVyPUOwMlMzPDNizszN NWXGS|V7W0GQR1XS
HMV-II MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjjTWM2OD1|MT6zOVkzKM7:TR?= M4D0[3NCVkeHUh?=
NCI-H2087 NXH3PVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fLfGlEPTB;M{GuOlM2OiEQvF2= NGTHNJFUSU6JRWK=
CAL-54 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXqSYNKSzVyPUOxMlczPDFizszN M3O5dHNCVkeHUh?=
HCC70 NFPW[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3UmlEPTB;M{KuNVM5PyEQvF2= NIrOeWJUSU6JRWK=
ES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN{LkOwOlIh|ryP NVPoNm9wW0GQR1XS
NCI-H1355 NWPzSpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLmSnFKSzVyPUOzMlIxPCEQvF2= MV7TRW5ITVJ?
CFPAC-1 NEPRd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN|LkKzN|Ih|ryP MX\TRW5ITVJ?
MKN28 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN|LkO4NFkh|ryP MkD1V2FPT0WU
HDLM-2 NEL3TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDlXWVKSzVyPUOzMlY6OzFizszN NFnOWolUSU6JRWK=
PANC-10-05 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHm[pNKSzVyPUO0MlExOTRizszN MkfzV2FPT0WU
SAS MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILaTXdKSzVyPUO0MlQ2PjVizszN M1\ReHNCVkeHUh?=
HCC1395 NG\ye2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjHU5ZKSzVyPUO0MlcyQDZizszN MmHUV2FPT0WU
8305C M2LMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS3NIZHUUN3ME2zOU45PDF3IN88US=> M3SySXNCVkeHUh?=
KM12 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1|Nj63OVQ4KM7:TR?= NITSU21USU6JRWK=
SW1116 M2\KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDBNVV4UUN3ME2zO{42QTl{IN88US=> MXTTRW5ITVJ?
SK-MEL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\qTWM2OD1|OD6zN|g6KM7:TR?= NWLqRZZPW0GQR1XS
HCC2218 M2PMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[3eXNKSzVyPUO4MlY2OTlizszN M4r3bXNCVkeHUh?=
T84 M4LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiwTWM2OD1|OD63OFA6KM7:TR?= M1mzcnNCVkeHUh?=
ETK-1 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN7LkCyNkDPxE1? NYXHSmRSW0GQR1XS
COLO-800 NYLXUHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN7LkO4Olgh|ryP MYHTRW5ITVJ?
CAL-12T M1;qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XqfWlEPTB;M{muOVI5OSEQvF2= NF2xN5JUSU6JRWK=
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfyXVFoUUN3ME20NE41QTFzIN88US=> MUjTRW5ITVJ?
SJSA-1 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7oTFFKSzVyPUSxMlE2QTZizszN NVfYOow1W0GQR1XS
PSN1 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT2e2VKSzVyPUSxMlE4PDlizszN NYS1ZVVuW0GQR1XS
D-566MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e2eWlEPTB;NEGuNlA5PiEQvF2= NWLEb|NWW0GQR1XS
EGI-1 M3rP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTTTWM2OD12Mj60Nlgh|ryP MUnTRW5ITVJ?
A204 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPycIVKSzVyPUSyMlY{QDhizszN NYLYZWo5W0GQR1XS
Saos-2 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XaPGlEPTB;NEKuPFM3QSEQvF2= NFT6UZNUSU6JRWK=
SNU-C2B MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2XIpKSzVyPUSzMlY5PzhizszN M3L2VnNCVkeHUh?=
HLE M1S4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjXTWM2OD12ND6wPFU3KM7:TR?= MXHTRW5ITVJ?
SW1463 NF3tV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvIUopVUUN3ME20OE46QTdzIN88US=> M4DicXNCVkeHUh?=
DSH1 NX71XXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jOZWlEPTB;NEWuNFA{OyEQvF2= M3j3d3NCVkeHUh?=
MCF7 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7PTWM2OD12NT61NFUyKM7:TR?= MYTTRW5ITVJ?
K5 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDWWXpKSzVyPUS1Mlk1ODVizszN NF3GSXFUSU6JRWK=
NCI-H358 NHniSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETQUXFKSzVyPUS3MlIyPSEQvF2= NYOwOZVnW0GQR1XS
NCI-H2030 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXTTWM2OD12Nz6yN|c1KM7:TR?= MnzMV2FPT0WU
SW948 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR5LkS2OEDPxE1? MVnTRW5ITVJ?
BALL-1 M2rQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jwSmlEPTB;NEeuOlE3QCEQvF2= NV7RfG1VW0GQR1XS
TE-9 M2H1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR5Lkm1PFEh|ryP MV3TRW5ITVJ?
SK-N-FI NYfHXYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTqVnhnUUN3ME20PE4xOzV6IN88US=> MX7TRW5ITVJ?
KALS-1 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTR6LkGyPFkh|ryP NIPtZ|BUSU6JRWK=
HO-1-N-1 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;1[2JYUUN3ME20PE44PDR3IN88US=> M{[3VnNCVkeHUh?=
NCI-H2452 NWHMT5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnJTWM2OD12OT6xNVUzKM7:TR?= M1nwe3NCVkeHUh?=
OC-314 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\t[45KSzVyPUS5MlY5OzRizszN NGn1fY5USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Active not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID